Does Medicare Cover Ozempic? What GLP-1 Drugs Cost on Medicare in 2026

Will Medicare Pay for GLP-1 Weight Loss Drugs in 2026?

Yes — and the price tag is the headline. From July 1, 2026, the Medicare GLP-1 Bridge program puts Wegovy and Zepbound at a $50/month cap for qualifying Part D members, down from four-figure retail pricing.

CMS (the Centers for Medicare & Medicaid Services) confirmed the Medicare GLP-1 Bridge program on March 5, 2025 — the first time Part D has ever picked up the tab for anti-obesity GLP-1 medications.¹ The discounted coverage window opens July 1, 2026 and stays open through December 31, 2026.

The reason this matters to your wallet: for two decades the Social Security Act barred Medicare from paying for any drug prescribed purely for weight loss, leaving seniors to absorb the full cash price. The TREAT Obesity Act, folded into the bipartisan budget deal signed in late 2025, rewrote that rule and ordered CMS to stand up a transitional, reduced-cost program.²

Think of the Bridge as a six-month price-relief window while CMS finishes building the larger BALANCE Model, which arrives in January 2027 with a wider drug list, outcome-based manufacturer pricing, and built-in behavioral health support.

By the Office of the Actuary's math, roughly 3.4 million Medicare beneficiariesshould clear the bar for the $50 rate — though how many actually claim it will hinge on prescriber bandwidth and how widely the savings get publicized.³

How Much Does Ozempic-Class GLP-1 Coverage Cost on Medicare?

The most you'll pay is $50/month for a covered GLP-1 under the Bridge program — up to 96% less than the $998–$1,349 you'd face buying it without insurance.

One number does all the work here: $50 a month. That's the hard ceiling on what a Medicare beneficiary spends out of pocket for a covered GLP-1 during the Bridge window — you cannot be charged more.⁴

Compare that to the alternatives. List price for these injections runs $900 to $1,350 a monthif you're paying cash with no coverage. Even commercially insured patients commonly land at $150–$300/month once copays and deductibles are factored in. Against the cash price, the $50 Bridge rate is a cut of as much as 96% — the single cheapest legal route to brand-name GLP-1s for anyone on Medicare.

What's behind the $50 figure:

• One flat copay, either drug:The $50 cap is identical whether you're filling Wegovy or Zepbound — it's a fixed dollar copay, not a percentage coinsurance that swings with list price.⁵
• Deductible doesn't touch it:The Part D deductible doesn't apply to the Bridge copay. Your very first fill costs $50, not full price.
• Drugmakers eat the difference: Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) both signed off on steep rebates to CMS to make $50 work. The exact figures are confidential, but analysts peg the discounts at 60–75% of list price.⁶
• Won't burn your catastrophic cap:Bridge spending doesn't count toward the Part D out-of-pocket maximum ($2,000 in 2026 under the Inflation Reduction Act), so your other drug costs keep their own ceiling intact.

Which GLP-1 Drugs Get the $50 Medicare Price?

Only two drugs qualify for the discounted Bridge rate: Wegovy (semaglutide, Novo Nordisk) and Zepbound (tirzepatide, Eli Lilly) — both FDA-approved for obesity.

The $50 cap is narrow on purpose. It applies to exactly two FDA-approved anti-obesity medications:

Drugs That Won't Get the $50 Rate

Just as important for your budget is knowing what the Bridge price does notcover — so you don't assume a $50 fill and get hit with the full cost:

• Ozempic(semaglutide 0.5mg/1mg/2mg) — labeled for type 2 diabetes, not weight loss, so it sits outside the Bridge. The upside: Medicare already pays for Ozempic under standard Part D when it's prescribed for diabetes, so your diabetes coverage is unaffected.⁷
• Mounjaro(tirzepatide) — the diabetes-branded twin of Zepbound. Same molecule, different label; it's covered for diabetes under Part D but not under the obesity Bridge.
• Compounded semaglutide or tirzepatide — even though compounded versions are often the cheapest cash option, only FDA-approved brand products earn the $50 rate. 503A/503B compounds are excluded.
• Rybelsus(oral semaglutide) — currently a diabetes-only label, so the pill form doesn't qualify for the obesity Bridge pricing.
• Saxenda (liraglutide) — an older, less effective GLP-1 for obesity; not on the Bridge list.

Who Qualifies for the $50 Medicare GLP-1 Price?

You get the discounted rate if you carry Medicare Part D (PDP or MA-PD), have a BMI of 30+ (or 27+ with a weight-related condition), and your prescriber clears prior authorization.

Three boxes have to be checked before the $50 price kicks in — you need all of them, not just one:⁸

1. You carry drug coverage

You need active enrollment in a Medicare Part D prescription drug plan (PDP) or a Medicare Advantage plan that includes drug coverage (MA-PD)for 2026. Original Medicare (Parts A and B) on its own has no drug benefit, so it won't get you the $50 price.

Good news for your wallet: there's no shopping around required. Every Part D PDP and MA-PD is mandated to honor the Bridge pricing, so your current plan already counts.⁹

2. Your BMI and diagnosis check out

A prescriber has to document a clinical reason for an anti-obesity drug, which in practice means:

• BMI of 30 or greater (clinical obesity), OR
• BMI of 27 or greater with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

These mirror the same FDA-label thresholds used for any Wegovy or Zepbound prescription. Your doctor records the BMI and any qualifying condition in your chart to unlock the price.

3. A qualified prescriber writes the script

The prescription has to come from a licensed provider — an MD/DO, nurse practitioner, or physician assistant cleared to prescribe in your state. CMS layered on no extra prescriber hurdles beyond the usual state scope-of-practice rules.¹⁰

Telehealth counts. If you already see a virtual GLP-1 clinic, they can issue a Bridge-qualifying script and you keep the $50 price — provided that provider accepts Medicare.

Who misses out on the $50 rate

• Anyone on Original Medicare with no Part D drug plan attached
• Under-65 beneficiaries who have Medicare via disability but skipped Part D
• People on Medicaid but not Medicare — Medicaid sets its own GLP-1 rules state by state
• Anyone whose BMI falls short of the clinical thresholds
• Medicare Savings Program members, whose cost-sharing may differ — confirm with your plan

How Do You Lock In the $50 Bridge Price?

There's no sign-up form — the discount rides on your existing Part D plan. To claim it, confirm your Part D coverage, book a doctor visit, and clear prior authorization before July 1, 2026.

Here's the part people overpay for by accident: there is no separate Bridge enrollment. Hit the criteria above and the $50 pricing is automatic at your current Part D plan. The work is on the front end — get these four things in place:

BMI Rules and the Prior Auth That Unlocks the Price

To hit $50 you need a documented BMI of 30+ (or 27+ with a comorbidity such as hypertension or sleep apnea) plus a prior authorization your doctor files with your Part D plan.

Prior authorization is the step that most often delays — or blocks — the discounted price. Knowing what the plan looks for lets you get it right the first time.

What the plan checks before approving the rate

Once your doctor submits the prior auth, the Part D plan generally confirms:

• Your BMI qualifies (30+ or 27+ with comorbidity)
• The diagnosis is documented in medical records
• The prescriber is a qualified, Medicare-enrolled provider
• The specific medication requested (Wegovy or Zepbound) is on the plan formulary for the Bridge program

The CMS rules that speed up your approval

In its April 2026 final rule, CMS ordered Part D plans to run a "streamlined prior authorization" for Bridge drugs — fewer hoops between you and the $50 price.¹¹Specifically:

• Plans cannot impose step therapy requirements (e.g., requiring you try a cheaper drug first)
• Plans cannot require a minimum number of supervised diet attempts before approval
• Authorization decisions must be made within 72 hours for standard requests and 24 hours for expedited requests
• Initial authorization must cover the full titration and maintenance period through December 31, 2026

If you're denied (and stuck paying full price)

A denial means you'd face the full retail cost — but you can appeal, and the path is laid out:

1. Coverage determination redetermination — Request a review by your plan (7 days for standard, 72 hours for expedited)
2. Independent Review Entity (IRE) — If the plan upholds the denial, an independent body reviews the case
3. Administrative Law Judge (ALJ) hearing — For amounts over $190 (2026 threshold)

CMS expects denials to be uncommon thanks to the streamlined rules, but brace for slower turnaround in the opening months while plans wire up their systems — another reason to file early.¹²

CMS Balance Model: How It Sets Long-Term GLP-1 Prices (2026)

The CMS Balance Model (formally BALANCE — Behavioral and Lifestyle Approaches to Nutrition, Care, and Engagement) is the Medicare Innovation Center pilot built to keep a lid on the cost of expensive chronic-condition drugs, and GLP-1 obesity meds are its first test case. Run by the CMS Center for Medicare and Medicaid Innovation (CMMI), it ties value-based manufacturer contracts to wrap-around behavioral health, nutrition counseling, and lifestyle coaching.

On the drug-cost side, the Balance Model governs Wegovy and Zepbound under Part D. CMS strikes performance-linked rebates with Novo Nordisk and Eli Lilly that pay out based on real results — weight lost, cardiac events avoided, prescriptions actually refilled — instead of raw sales volume. Plans that join agree to one common prior-auth standard (BMI ≥ 30, or ≥ 27 with a qualifying comorbidity) and to enrolling members in lifestyle support.

2026 timeline: The six-month Bridge (July 1 – December 31, 2026) is the on-ramp and the cheap-pricing trial run. Full Balance Model coverage starts January 1, 2027, with the participating Part D and Medicare Advantage plans named in fall 2026 during open enrollment. CMS is projecting 20-plus plan sponsors and several million eligible members in year one.

What Will Wegovy or Zepbound Cost on Medicare in 2026?

From July 1, 2026, Medicare Part D covers both Wegovy (semaglutide) and Zepbound (tirzepatide) for weight loss — capped at $50/month under the obesity indication.It's the first time Medicare has put a price on GLP-1 drugs prescribed specifically for chronic weight management, closing out a two-decade ban under the Social Security Act.

That $50 rate runs through the Medicare GLP-1 Bridge program from July to December 2026, then rolls into permanent pricing under the CMS Balance Model on January 1, 2027. To get it, Part D members need a documented BMI ≥ 30 (or ≥ 27 with a qualifying comorbidity like hypertension, dyslipidemia, or sleep apnea) and a script from a Medicare-enrolled provider. Ozempic and Mounjaro keep their existing type 2 diabetes pricing and sit outside this weight-loss-specific discount.

What Happens to the Price When the Bridge Ends?

On January 1, 2027 the BALANCE Model takes over — permanent Medicare GLP-1 coverage with value-based manufacturer pricing and built-in behavioral health support.

The Bridge has a hard expiry: December 31, 2026. But the discounted-coverage era doesn't end there — it's where it really starts.

From January 1, 2027, CMS switches on the BALANCE Model(Beneficiary Access to Leveraged Anti-obesity and Nutrition Care for Equity) — the full, lasting structure for how Medicare prices and pays for obesity medications.¹³

Where BALANCE costs more (or less) than the Bridge

• Duration: BALANCE is a 10-year model (2027–2036), not a 6-month transition. It provides long-term coverage certainty.
• Broader drug coverage: While Bridge covers only Wegovy and Zepbound, BALANCE may include additional anti-obesity medications as they receive FDA approval (such as oral semaglutide for obesity, survodutide, or retatrutide).
• Value-based contracting: Manufacturers participating in BALANCE must agree to outcome-based rebates. If patients do not achieve specified weight loss thresholds, manufacturers refund a portion of the drug cost to Medicare.¹⁴
• Integrated behavioral support: BALANCE requires participating beneficiaries to have access to nutritional counseling and physical activity support, either through their provider or through a CMS-approved digital health program.
• What you'll actually pay:The Bridge's $50/month copay is not yet locked in for BALANCE. CMS keeps saying cost-sharing will be "affordable," but the precise dollar figure is still being negotiated as of May 2026 — so don't assume the $50 carries over unchanged.

Medicare $50 vs. Cash Pay vs. Commercial Insurance: The Cheapest Route

For a Medicare beneficiary, the Bridge wins outright at $50/month — versus $150–$300/month on typical commercial insurance, $349/month buying direct from LillyDirect, or a brutal $998–$1,349/month at retail with no coverage at all.

Numbers make the case better than adjectives. Here's what the same GLP-1 weight loss prescription actually costs you under every realistic payment route, side by side.

The takeaway is hard to miss: for Medicare members, nothing beats $50/month. It even undercuts the strongest commercial plans, and next to cash pay — where plenty of seniors have been bleeding $1,000-plus every month — the savings are in a different universe.

One catch worth flagging on cost: manufacturer savings cards generally don't work for Medicare beneficiaries. Federal anti-kickback law mostly bars drugmakers from buying down Medicare copays the way they do for the commercially insured.¹⁶The Bridge $50 rate is, in effect, Medicare's replacement for those coupons.

What to Do Now to Claim the $50 Price on Day One

Get ahead of it: verify your Part D enrollment, book a doctor visit to log your BMI, and have your prescriber line up the prior authorization before the July 1, 2026 launch.

The $50 window opens July 1, 2026 — only three months out. These are the concrete moves that put you first in line instead of paying full freight while you wait on paperwork.

Frequently Asked Questions